9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Lung Cancer

Estimated Enrollment: 28

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Disease Control Rate (DCR),  Response Rate,  ,

Interventions: Alisertib,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: May 2021

Completion Date: May 2022

Last  Posted Date: May 10, 2019

Location: University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT02293005

Was this article helpful?
Dislike 0